Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated ...

Pfizer's vaccine was 92% effective in preventing ... country for three weeks or return at a later date for the follow-up injection. Among them is former Argentine President Mauricio Macri.

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...

Pfizer’s once-weekly antibody injection for haemophilia A and B, marstacimab, could be on track for regulatory approvals based on solid results in a phase 3 trial reported over the weekend ...

Pfizer reckons it will make a whopping $22 ... run out of money and had stopped accepting new doses as it needs a cash injection of $5.2 billion to keep operating. "Pfizer…has made more than ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

Every fall and winter, the United States sees an uptick in the number of people who fall ill to influenza and other seasonal diseases. This flu season typically stretches from October to ...